Last reviewed · How we verify
DE-130A
DE-130A is a small-molecule inhibitor designed to modulate intraocular pressure and inflammation in the eye.
DE-130A is a small-molecule inhibitor designed to modulate intraocular pressure and inflammation in the eye. Used for Glaucoma or ocular hypertension (Phase 3 indication).
At a glance
| Generic name | DE-130A |
|---|---|
| Also known as | Catiolanze® |
| Sponsor | Santen SAS |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
DE-130A targets specific pathways involved in aqueous humor dynamics and ocular inflammation. The drug is being developed for ophthalmic conditions where reduction of intraocular pressure and anti-inflammatory effects are therapeutically beneficial.
Approved indications
- Glaucoma or ocular hypertension (Phase 3 indication)
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DE-130A CI brief — competitive landscape report
- DE-130A updates RSS · CI watch RSS
- Santen SAS portfolio CI